Which prostate cancers are not fatal, or have little impact on health? Clinically, doctors will grade the risk level of early prostate cancer according to the clinical stage, differentiation level and PSA (a tumor indicator of prostate cancer) level of the tumor, specifically, the risk level of prostate cancer is divided into three levels: low risk, intermediate risk and high risk. For most of the patients with low risk prostate cancer, no treatment can be done for the time being, as long as they are monitored closely and have PSA review every 6 months and prostate puncture biopsy every 12 months. “The most important thing is to have a biopsy. Of course, because prostate cancer patients vary so dramatically on an individual basis, reliance on PSA, clinical staging, and even pathological biopsies alone cannot yet accurately predict whether a particular patient’s prostate cancer is fatal. It is for this reason that our prostate cancer research team, with the support of the national “973” scientific research program, combined with our own original research results on the genetic aspects of prostate cancer treatment in Chinese, to build a prostate cancer early diagnosis and risk assessment prediction system suitable for Chinese people.